One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients
An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial
Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study
Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey
Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort
Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study
A Large-scale Digital Survey of Patients with Localized and Advanced Prostate Cancer in Germany, the UK, and the USA
Risk-based Prostate-specific Antigen Monitoring Reduces Follow-up Burden After Radical Prostatectomy
Oncological Outcomes in Patients with Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–detected Oligometastatic Prostate Cancer Treated with Metastasis-directed Radiotherapy as the Single Treatment Modality
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
Challenges in Follow-up After Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Insights from a Delphi Consensus
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer
Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial
Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis
Re: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al. Systemic Therapy in Patients with Metastatic Castration-resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 2025;43:2311–34
Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review
Neurovascular Structure-adjacent Frozen-section Examination (NeuroSAFE) During Radical Prostatectomy: A Systematic Review and Meta-analysis
Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives
Combined Prostate-specific Membrane Antigen Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer
Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data
Re: Francesca Ambrosini, Nataniele Piol, Matteo Bauckneht, et al. Immunohistochemical Prostate-specific Membrane Antigen (PSMA) Expression Patterns of Primary Prostate Cancer Tissue as a Determining Factor for Prostate Cancer Staging with PSMA Positron Emission Tomography/Computed Tomography. Eur Urol Oncol. In press. 10.1016/j.euo.2025.02.012
Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, and Rodolfo Montironi’s Letter to the Editor re: Francesca Ambrosini, Nataniele Piol, Matteo Bauckneht, et al. Immunohistochemical Prostate-specific Membrane Antigen (PSMA) Expression Patterns of Primary Prostate Cancer Tissue as a Determining Factor for Prostate Cancer Staging with PSMA Positron Emission Tomography/Computed Tomography. Eur Urol Oncol. In press. 10.1016/j.euo.2025.02.012
Re: Olivier Cussenot, Yoann Taille, Jean-Jacques Portal, et al. Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis. Eur Urol Oncol. 2025;8:871–874
Reply to Hinpetch Daungsupawong and Viroj Wiwanitkit’s Letter to the Editor re: Olivier Cussenot, Yoann Taille, Jean-Jacques Portal, et al. Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis. Eur Urol Oncol. 025;8:871–874
Re: Benedikt Hoeh, Felix Preisser, Fabio Zattoni, et al. Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval. Eur Urol Oncol 2025;8:372–9
Re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623–31
Reply to Hatice Bolek’s Letter to the Editor re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623–31
Re: Anna Lantz, Ying Li, Stefan Carlsson, et al. Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival—12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol Oncol. In press. 10.1016/j.euo.2025.05.004
Reply to Natália Dalsenter Avilez, Tomás Bernardo Costa Moretti, and Leonardo Oliveira Reis’ Letter to the Editor re: Anna Lantz, Ying Li, Stefan Carlsson, et al. Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival—12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol Oncol. In press. 10.1016/j.euo.2025.05.004
Re: Nicolas A. Soputro, Carter D. Mikesell, Salim K. Younis, et al. Propensity-matched Comparison of Single-port Transvesical Versus Standard Multiport Robotic Radical Prostatectomy. Eur Urol Oncol. In press. 10.1016/j.euo.2025.05.023
Reply to Fabrizio Di Maida, Carlo Andrea Bravi, Marcio Covas Moschovas, et al’s Letter to the Editor re: Nicolas A. Soputro, Carter D. Mikesell, Salim K. Younis, et al. Propensity-matched Comparison of Single-port Transvesical Versus Standard Multiport Robotic Radical Prostatectomy. Eur Urol Oncol. In press. 10.1016/j.euo.2025.05.023
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes After 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Comment on: Active Surveillance of Grade Group 2 Prostate Cancer- Oncological Outcomes from a Contemporary European Cohort
Reply to Isabel Heidegger and Jasmin Bektic’s Letter to the Editor re: Michael Baboudjian, Riccardo Leni, Marco Oderda, et al., Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. Eur Urol Oncol. 2025;8:1257–1263
